News articles about ImmuCell (NASDAQ:ICCC) have trended somewhat positive on Monday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmuCell earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.9010124121312 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, TheStreet upgraded shares of ImmuCell from a “c” rating to a “b-” rating in a research report on Monday, June 12th.

ImmuCell (NASDAQ:ICCC) traded up 1.80% during trading on Monday, hitting $7.70. 5,403 shares of the stock traded hands. The stock has a market cap of $37.33 million, a P/E ratio of 53.85 and a beta of 1.02. ImmuCell has a 52-week low of $4.76 and a 52-week high of $8.24. The stock has a 50 day moving average price of $7.00 and a 200-day moving average price of $6.06.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Thursday, May 11th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter. ImmuCell had a net margin of 16.49% and a return on equity of 11.69%. The business had revenue of $3.54 million for the quarter.

In other news, insider Brian L. Pessin bought 30,000 shares of the stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of $5.25 per share, for a total transaction of $157,500.00. Following the purchase, the insider now directly owns 70,000 shares of the company’s stock, valued at approximately $367,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at

About ImmuCell

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.